Does Rallies show 13F holders for NGNE?

Yes. Rallies tracks hedge fund and 13F ownership data for NGNE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NGNE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NGNE. It does not provide personalized investment advice.

NGNE (Neurogene, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Neurogene, Inc. Common Stock (NGNE) is a publicly traded Healthcare sector company. As of May 21, 2026, NGNE trades at $27.19 with a market cap of $442.14M and a P/E ratio of -6.31. NGNE moved +0.28% today. Year to date, NGNE is +46.23%; over the trailing twelve months it is +45.28%. Its 52-week range spans $6.88 to $74.49. Analyst consensus is strong buy with an average price target of $81.67. Rallies surfaces NGNE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NGNE stock?

Hedge funds tracked by Rallies that own NGNE include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Neurogene, Inc. Common Stock.

NGNE Key Metrics

Key financial metrics for NGNE
Metric	Value
Price	$27.19
Market Cap	$442.14M
P/E Ratio	-6.31
EPS	$-4.24
Dividend Yield	0.00%
52-Week High	$74.49
52-Week Low	$6.88
Volume	145.97K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-90.35M
Gross Margin	0.00%

Top Hedge Funds Holding NGNE

Redmile Group holds 1.46M shares of NGNE, changed +0.00% as of Mar 31, 2026.

Latest NGNE News

Neurogene to Present ICV NGN-401 Data Showing Superior Brain Biodistribution — Apr 28, 2026
Neurogene Secures FDA Breakthrough Designation for Rett Therapy After Phase 1/2 Data — Feb 27, 2026
Neurogene Plans Mid-2026 NGN-401 Update After Q4 2025 Pivotal Dosing — Feb 14, 2026

Recent NGNE Insider Trades

Cvijic Christine Mikail sold 4.80K (~$144.35K) on May 6, 2026.
Cvijic Christine Mikail sold 4.80K (~$155.69K) on May 6, 2026.
Cvijic Christine Mikail sold 2.56K (~$55.32K) on Mar 26, 2026.

NGNE Analyst Consensus

8 analysts cover NGNE: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $81.67.

Common questions about NGNE

Who owns NGNE stock?: Hedge funds tracked by Rallies that own NGNE include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Neurogene, Inc. Common Stock.
Does Rallies show 13F holders for NGNE?: Yes. Rallies tracks hedge fund and 13F ownership data for NGNE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NGNE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NGNE. It does not provide personalized investment advice.